Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised

Glaukos Corporation GKOS posted second-quarter loss per share of 11 cents, wider than the Zacks Consensus Estimate of a loss of 10 cents. This compares to a loss per share of 15 cents a year ago.

The Zacks Rank #4 (Sell) company’s quarterly sales totaled $58.6 million, which beat the Zacks Consensus Estimate by 4.3%. On a year-over-year basis, revenues surged 35.8%.

Quarter Details

Gross profit in the second quarter was $50.7 million, up 37.1% year over year. Gross margin quarter was 86.6% of net revenues, up 90 basis points on a year-over-year basis.

Operating expenses increased 38.1% to $57 million on a year-over-year basis driven by growth in domestic sales as well as higher marketing and administrative personnel and expenses. These apart, Glaukos’ expansion of global direct sales infrastructure and increased spending associated with pharmaceutical research and clinical trials drove operating expenses.

Glaukos Corporation Price, Consensus and EPS Surprise

 

Glaukos Corporation Price, Consensus and EPS Surprise

Glaukos Corporation price-consensus-eps-surprise-chart | Glaukos Corporation Quote

 

Guidance Raised

Glaukos now expects revenues within $226 million-$231 million, up from the previously stated $225-$230 million. The Zacks Consensus Estimate is pegged at $228.2 million, within the guided range.

Our Take

Glaukos exited the second quarter on a tepid note. However, a raised guidance instils optimism in the stock. Also, the company is currently progressing with the U.S. commercial rollout of its next-generation iStent inject Trabecular Micro-Bypass device. For iDose Travoprost, Glaukos targets to file an FDA approval in the near future. Expansion in gross margin is a positive. Management is optimistic about the recent Avedro buyout.

On the flip side, surging operating expenses raise concern. Glaukos also faces cut-throat competition in the Medical Devices space. Further, an overtly stringent regulatory-approval process for the iDose platform is concerning.

Earnings of MedTech Majors at a Glance

A few top-ranked companies, which posted solid results this earnings season, are Stryker Corporation SYK, Baxter International Inc. BAX and Intuitive Surgical, Inc. ISRG, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Stryker delivered second-quarter 2019 adjusted earnings per share of $1.98, beating the Zacks Consensus Estimate by 2.6%. Its revenues of $3.65 billion surpassed the consensus estimate by 1.4%.

Baxter delivered second-quarter 2019 adjusted earnings per share of 89 cents, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Its revenues of $2.84 billion outpaced the consensus estimate of $2.79 billion by 1.9%.

Intuitive Surgical reported second-quarter 2019 adjusted earnings per share of $3.25, which beat the Zacks Consensus Estimate of $2.85. Its revenues of $1.1 billion surpassed the consensus mark of $1.03 billion.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Glaukos Corporation (GKOS) : Free Stock Analysis Report
 
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
 
Stryker Corporation (SYK) : Free Stock Analysis Report
 
Baxter International Inc. (BAX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research